Lilly claims fast FDA review for Emgality in cluster headacheEli Lilly has a battle on its hands in the migraine prevention category with third-to-market CGRP inhibitor Emgality Share XLilly claims fast FDA review for Emgality in cluster headachehttps://pharmaphorum.com/news/lilly-claims-fast-fda-review-for-emgality-in-cluster-headache/
Lilly joins CGRP race to cure migraineEli Lilly are gearing up to announce details from the latest Emgality analysis, which can potentially push the Share XLilly joins CGRP race to cure migrainehttps://pharmaphorum.com/news/lilly-joins-cgrp-race-to-cure-migraine/
